斯普林沃克斯治疗公司对米尔达美替尼布提出了有前途的新数据,显示它可以减少瘤并改善NF1患者的寿命. SpringWorks Therapeutics presents promising new data on mirdametinib, showing it reduces tumors and improves life for NF1 patients.
春季疗法公司将介绍关于mirdametinib的新数据,这是一种治疗神经纤维素瘤1型相关瘤的药物,显示瘤显著减少和改善患者的生活质量. SpringWorks Therapeutics will present new data on mirdametinib, a drug for neurofibromatosis type 1-associated tumors, showing significant tumor reduction and improved quality of life for patients. 该药物在治疗小儿科低年级性微瘤方面也显示出希望。 The drug also showed promise in treating pediatric low-grade glioma. 林业发展局批准了该药物关于治疗NF1-PN的优先审查申请,预计将于2025年2月作出决定。 The FDA has granted the drug's application for treating NF1-PN a Priority Review, with a decision expected by February 2025.